Cutia Therapeutics (HK:2487)
:2487
Want to see HK:2487 full AI Analyst Report?
2487 Stock Chart & Stats
HK$4.59
-HK$0.09(-1.60%)
At close: 4:00 PM EST
HK$4.59
-HK$0.09(-1.60%)
Day’s Range― - ―
52-Week RangeHK$3.81 - HK$12.84
Previous CloseN/A
Volume1.53M
Average Volume (3M)399.60K
Market Cap
HK$1.50B
Enterprise ValueHK$1.35B
Total Cash (Recent Filing)HK$789.16M
Total Debt (Recent Filing)HK$317.53M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding364,730,870
10 Day Avg. Volume272,590
30 Day Avg. Volume399,603
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.52
Price to Sales (P/S)4.01
P/FCF Ratio-4.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$7.45Price Target Upside62.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)HK$588.44M
Bulls Say, Bears Say
Bulls Say
Revenue Growth MomentumSustained, material revenue acceleration (30.8% in 2025) indicates stronger product adoption and expanding market penetration. Over a multi-quarter horizon this growth can enable operating leverage: higher sales spread fixed R&D and SG&A costs, improving the path to break-even if maintained.
Healthy Gross MarginsA ~45.7% gross margin signals solid underlying unit economics and pricing power in core offerings. Durable gross margins give the company room to invest in R&D and sales while preserving the potential for margin expansion as revenue scales, supporting long-term profitability prospects.
Manageable Leverage & Equity BaseRelatively low debt-to-equity (~0.36) and a sizable equity buffer reduce near-term solvency risk while the firm invests in growth. This balance-sheet resilience facilitates access to capital markets and provides a cushion to absorb losses during commercialization and R&D investment phases.
Bears Say
Deep UnprofitabilityVery large negative operating and net margins show the business remains far from break-even and is heavily investment-driven. Persistent deep losses will erode capital over time, force reliance on external funding, constrain strategic flexibility, and prolong the timeline to durable profitability absent structural cost or revenue changes.
Negative Cash Flow / Cash BurnSustained negative operating and free cash flow means the company must continue to secure external financing to fund operations and R&D. Although cash burn improved from 2024, ongoing outflows raise dilution and refinancing risk and limit the firm's ability to self-fund growth or opportunistic investments.
Eroding Equity & Negative ROENegative ROE and declining equity reflect shareholder value erosion driven by recurring losses. This weakens the capital base, reduces financial flexibility for acquisitions or scaling, and increases vulnerability to funding shocks if losses persist, complicating long-term strategic execution.
Cutia Therapeutics News
2487 FAQ
What was Cutia Therapeutics’s price range in the past 12 months?
Cutia Therapeutics lowest stock price was HK$3.81 and its highest was HK$12.84 in the past 12 months.
What is Cutia Therapeutics’s market cap?
Cutia Therapeutics’s market cap is HK$1.50B.
When is Cutia Therapeutics’s upcoming earnings report date?
Cutia Therapeutics’s upcoming earnings report date is Aug 27, 2026 which is in 98 days.
How were Cutia Therapeutics’s earnings last quarter?
Cutia Therapeutics released its earnings results on Mar 24, 2026. The company reported -HK$0.304 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.304.
Is Cutia Therapeutics overvalued?
According to Wall Street analysts Cutia Therapeutics’s price is currently Undervalued.
Does Cutia Therapeutics pay dividends?
Cutia Therapeutics does not currently pay dividends.
What is Cutia Therapeutics’s EPS estimate?
Cutia Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cutia Therapeutics have?
Cutia Therapeutics has 364,730,870 shares outstanding.
What happened to Cutia Therapeutics’s price movement after its last earnings report?
Cutia Therapeutics reported an EPS of -HK$0.304 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.951%.
Which hedge fund is a major shareholder of Cutia Therapeutics?
Currently, no hedge funds are holding shares in HK:2487
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cutia Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.34%
12-Months-Change
Fundamentals
Return on Equity
-41.22%
Trailing 12-Months
Asset Growth
-1.87%
Trailing 12-Months
Company Description
Cutia Therapeutics
Cutia Therapeutics operates as a biopharmaceutical company that develops a dermatology platform for skin and scalp diseases. The company focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company was incorporated in 2019 and is based in Shanghai, China with additional offices in Beijing, Wuxi and Hong Kong.
2487 Stock 12 Month Forecast
Average Price Target
HK$7.45
▲(62.31% Upside)
Technical Analysis
JW (Cayman) Therapeutics Co. Ltd.
―
Mabpharm Limited
―
Sirnaomics Ltd.
―
SinoMab Bioscience Ltd.
―
Transcenta Holding Limited
―
Options Prices
Currently, No data available
---